Trodelvy (Sacituzumab govitecan-hziy) injection is a Trop-2-directed ADC and topoisomerase inhibitor conjugate approved to treat adults with:

  • Unresectable locally advanced or mTNBC (metastatic triple-negative breast cancer) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease.
  • Unresectable locally advanced or metastatic hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have been treated with endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
  • Locally advanced or metastatic urothelial cancer (mUC) who have previously been treated with platinum-containing chemo and either PD-1 (which stands for programmed death receptor-1) or PDL1 (which stands for programmed death-ligand 1 inhibitor).

Posology & Administration: The recommended dose of Trodelvy (Sacituzumab govitecan-hziy) injection is 10 mg/kg given as an IV infusion once a week on Days 1 & 8 of 21-day therapy cycles until disease progression or in case of unacceptable toxicity. Do not administer doses of Trodelvy more than 10 mg per kg. Trodelvy needs to be administered as an intravenous (IV) infusion only. Avoid administering as an intravenous (IV) push or bolus.

 

  • First infusion: Administer intravenous (IV) infusion over three hours. Observe patients throughout the infusion and for at least 30 minutes after the initial dose to notice/see any sign or symptom of infusion-related reactions.
  • Subsequent infusions: Administer intravenous (IV) infusion over 1 to 2 hours if previous infusions were tolerated. Observe patients throughout the IV infusion and for at least 30 minutes following the IV infusion.